Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

A. Pillai, P. Teo, T. George, A. Mukhopadhyay, S. Dejbakhsh-Jones, S. Strober

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

The goal of the current study was to determine whether whole bone marrow cells or splenic CD8+ T cells from C57BL/6 (H-2b) donor mice, which are tolerant to BALB/c (H-2d) alloantigens, are capable of mediating graft anti-tumor activity against a BALB/c B-cell lymphoma after injection into irradiated BALB/c hosts. The experimental results show that high doses of splenic CD8+ T cells mixed with T cell-depleted bone marrow cells from C57BL/6 non-tolerant (normal) donors eliminate the BCL1 B-cell lymphoma cells and induce lethal graft-versus-host disease (GVHD). CD8+ T cells from tolerant donors simultaneously lose both their ability to induce GVHD and their anti-tumor activity. Whole bone marrow cell transplants from normal donors eliminated BCL1 tumor cells without inducing GVHD, and bone marrow cells from tolerant donors failed to eliminate the tumor cells. The infused BCL1 tumor cells expressed an immunogenic tumor-specific idiotype antigen disparate from host alloantigens, indicating that recognition of the tumor-specific antigen alone was insufficient to elicit graft anti-tumor activity from unimmunized allotolerant donor splenic CD8+ T cells or whole bone marrow cells. We conclude that CD8+ T cells from unimmunized normal donor mice require alloantigen recognition to mediate their anti-tumor activity following allogeneic BMT.

Original languageEnglish (US)
Pages (from-to)487-497
Number of pages11
JournalBone Marrow Transplantation
Volume40
Issue number5
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this